Clinical trials enrolling follicular lymphoma (FL) patients typically require bone marrow biopsies (BMBs) at baseline and at a subsequent point if complete response is achieved. These procedures are painful, take time and add cost. We hypothesized that BMBs do not provide information significant for response assessment in most follicular lymphoma patients on clinical trials. We identified 99 patients treated on clinical trials for follicular lymphoma between 2000 and 2016. BMBs resulted in a possible response assessment change in 1Á0% of patients (95% confidence interval: 0Á0-5Á5%). We conclude that mandatory BMBs at baseline and for response assessment are unnecessary in clinical trials for follicular lymphoma.
In 1999, the International Working Group (IWG) established bone marrow biopsies (BMBs) as part of response criteria for non-Hodgkin lymphoma patients treated on clinical trials (Cheson et al, 1999) . If BMBs are positive prior to treatment, the procedure should be repeated in patients with a complete response (CR) on imaging in order to confirm the response. The revised response criteria in 2007 and again in 2014 maintained this recommendation (Cheson et al, 2007 (Cheson et al, , 2014 . The utility of BMBs is being re-evaluated in some lymphoma subtypes, partly because of the high sensitivity of positron emission tomography/computed tomography (PET/CT) to detect extensive disease. The Lugano Classification no longer requires BMBs at initial assessment for Hodgkin lymphoma, a disease in which bone marrow involvement is rare (Cheson et al, 2014) . Recent studies have also questioned the importance of BMBs for other subtypes including diffuse large Bcell lymphoma and follicular lymphoma (Berthet et al, 2013; Khan et al, 2013; Perry et al, 2016; Ujjani et al, 2016) . Bone marrow involvement is frequently noted in follicular lymphoma and, therefore, in the clinical trial setting, BMBs continue to be recommended for follicular lymphoma patients at baseline and after a CR has been obtained on imaging in order to verify the complete response (Cheson et al, 1999 (Cheson et al, , 2007 (Cheson et al, , 2014 . Patients with negative baseline BMBs are anticipated to also have negative post-treatment BMBs, and therefore these studies are not required to be repeated following treatment. Those with positive baseline BMBs whose posttreatment imaging shows either partial response (PR), stable disease (SD), or progressive disease (PD) do not undergo repeat BMBs as these patients clearly have active disease regardless of BMB results. Therefore the only follicular lymphoma patients in whom BMBs could possibly affect response assessment are those with positive BMBs at baseline who have a CR on post-treatment imaging but residual disease in their bone marrow. We hypothesized that this represents a small percentage of patients undergoing treatment on clinical trials for follicular lymphoma, and therefore that BMBs might only rarely provide information necessary for accurate response assessment.
Methods
We obtained Institutional Review Board approval and identified newly diagnosed and relapsed/refractory follicular lymphoma patients treated on clinical trial protocols at Weill Cornell Medical College between 2000 and 2016 on whom BMBs were performed at enrolment. We collected results of baseline and post-treatment imaging and bone marrow examinations, using the response assessment criteria applicable at the time the study was conducted. We prospectively defined 10% as the threshold for significance; therefore, if our analysis determined that BMBs were relevant for short report First published online 5 July 2017 doi: 10.1111/bjh.14839 response assessment in less than 10% of patients, then we would conclude that BMBs are not useful for response assessment for follicular lymphoma patients on clinical trials. Ninety-five percent confidence interval (95% CI) for proportion was calculated using Clopper-Pearson exact binomial method.
Results and Discussion
A total of 99 follicular lymphoma patients who were treated on 32 clinical trials at Weill Cornell Medical College between 2000 and 2016 and underwent baseline BMBs were identified. The 2007 IWG revised criteria was the most frequently used method for response assessment (Cheson et al, 2007) . Table I lists patient characteristics. Median age was 61 years (29-87). The majority of patients (95/99) had advanced stage disease. Thirty-four were newly diagnosed and 65 were relapsed or refractory; 58/65 had received prior rituximab. Of the 32 clinical trials, 8 enrolled newly diagnosed patients and the remainder enrolled relapsed or refractory patients. Chemotherapy was part of the experimental regimen in 7 trials and anti-CD20 directed therapy in 20 trials. The non-chemotherapy trials primarily included targeted drugs; the most common agents were ibrutinib, idelalisib and lenalidomide (N = 34 patients). Figure 1 displays the results of baseline BMBs and posttreatment imaging studies and BMBs. Forty-five patients had positive BMBs at baseline (16 untreated, 29 previously treated). Of these 45 patients, post-treatment imaging studies demonstrated 12 CR, 19 PR, 5 SD and 9 PD. Eleven of the 12 patients with CR by imaging criteria had negative posttreatment BMBs that confirmed the CR. One patient did not undergo a post-treatment BMB despite having a CR on imaging. Eight of the patients with CR on imaging were newly diagnosed and 4 were previously treated. The clinical trial regimen included chemotherapy for 3 of the 12 patients (1 untreated, 2 relapsed/refractory). At most, in only 1 patient of the 99 (1Á0%, 95% CI: 0Á0-5Á5%) in this analysis would the BMB have potentially been relevant to response assessment. For the remaining patients who had negative baseline BMBs (N = 54), the results of post-treatment imaging and repeat BMBs are displayed in Fig 1; BMBs proved to be irrelevant to response assessment as previously described. Of note, 3 patients who underwent repeat BMBs were found to have myelodysplastic syndrome. Two of these 3 patients had negative baseline BMBs and one also had follicular lymphoma observed on post-treatment imaging and BMB -therefore this information did not change the patients' response assessment. Bone marrow evaluation in such cases should be guided by clinical parameters (e.g. cytopenias) irrespective of trial requirements.
Based on the results of this study, we conclude that BMBs do not meaningfully impact response assessment in patients treated on clinical trials for follicular lymphoma. If the disease is in complete remission by imaging, we find that bone marrow disease responds as well -and probably below the threshold of detection on a BMB.
Those developing response criteria for follicular lymphoma can omit bone marrow assessments without any evident loss of rigour. Baseline and post-treatment marrow sampling offer no additional value to radiographic imaging in assessing the depth of response. Marrow assessment at both time points may be able to be eliminated from protocols unless justified by some other rationale. If clinical scenarios warrant, BMBs may provide important information. However, our data indicate that BMBs should not be routinely included in follicular lymphoma clinical trials specifically for the purposes of response assessment as the discomfort, time and expense do not appear to be merited. Exposing a research subject to testing that is highly unlikely to add useful information is problematic. Validating these results in a larger data set will promote a patient-centred approach, as omission of the requirement for routine BMBs in clinical trials for follicular lymphoma may increase patient interest in study participation and improve protocol compliance.
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